MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.hrthm.2022.01.013

Медицинская библиотека · Heart rhythm · 2022

Subcutaneous versus transvenous implantable defibrillator in patients with hypertrophic cardiomyopathy.

Jankelson Lior, Garber Leonid, Sherrid Mark, Massera Daniele, Jones Paul, Barbhaiya Chirag, Holmes Douglas, Knotts Robert, Bernstein Scott, Spinelli Michael, Park David, Aizer Anthony, Chinitz Larry

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiomyopathy. The implantable cardioverter-defibrillator (ICD) is important for prevention of sudden cardiac death (SCD) in patients at high risk. In recent years, the subcutaneous implantable cardioverter-defibrillator (S-ICD) has emerged as a viable alternative to the transvenous implantable cardioverter-defibrillator (TV-ICD). The S-ICD does not require intravascular access; however, it cannot provide antitachycardia pacing (ATP) therapy.

OBJECTIVE

The purpose of this study was to assess the real-world incidence of ICD therapy in patients with HCM implanted with TV-ICD vs S-ICD.

METHODS

We compared the incidence of ATP and shock therapies among all HCM patients with S-ICD and TV-ICD enrolled in the Boston Scientific ALTITUDE database. Cumulative Kaplan-Meier incidence was used to compare therapy-free survival, and Cox proportional hazard ratios were calculated. We performed unmatched as well as propensity match analyses.

RESULTS

We included 2047 patients with TV-ICD and 626 patients with S-ICD, followed for an average of 1650.5 ± 1038.5 days and 933.4 ± 550.6 days, respectively. Patients with HCM and TV-ICD had a significantly higher rate of device therapy compared to those with S-ICD (32.7 vs 14.5 therapies per 100 patient-years, respectively; P <.001), driven by a high incidence of ATP therapy in the TV-ICD group, which accounted for >67% of therapies delivered. Shock incidence was similar between groups, both in the general and the matched cohorts.

CONCLUSION

Patients with HCM and S-ICD had a significantly lower therapy rate than patients with TV-ICD without difference in shock therapy, suggesting potentially unnecessary ATP therapy. Empirical ATP programming in patients with HCM may be unbeneficial.

Для цитирования: Jankelson Lior, Garber Leonid, Sherrid Mark, Massera Daniele, Jones Paul, Barbhaiya Chirag, Holmes Douglas, Knotts Robert, Bernstein Scott, Spinelli Michael, Park David, Aizer Anthony, Chinitz Larry. Subcutaneous versus transvenous implantable defibrillator in patients with hypertrophic cardiomyopathy.. Heart rhythm. 2022. DOI: 10.1016/j.hrthm.2022.01.013.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.